Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company listed on the Nasdaq that develops therapies for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions, has become one of the most volatile names in the small-cap biotech universe. The question facing investors is whether the shares, which recently traded near $0.50, can climb back to the $1.00 milestone.
There is no current, credible analyst consensus for NMRA. The most recent attributable analyst price targets were issued in late 2025, when the shares traded near $2.65, and they are now clearly stale. Those targets included a $14 objective from Yatin Suneja at Guggenheim (Buy), an $8 target from Ami Fadia at Needham, a $7 target from Brian Abrahams at RBC Capital (upgraded to Outperform), a $5 target from Graig Suvannavejh at Mizuho (Buy), and a $3 target from Paul Matteis at Stifel (Hold). The arithmetic mean of those five targets is approximately $7.40, with a range of $3 to $14.
Because the shares have since declined roughly 85% from those levels, these targets no longer represent a realistic forward view and are not used as the central target here. Instead, the $1.00 objective reflects a fallback approach based on a technical and psychological recovery level that is publicly discussed for beaten-down biotech names, rather than an analyst consensus.
The latest verified price for NMRA is about $0.50, with a 52-week range of roughly $0.32 to $3.65 and a market capitalization near $93 million. Reaching $1.00 would require an upside of roughly 100% from current levels, a substantial move by any measure.
Neumora is a clinical-stage company with no approved products and negative earnings per share (EPS). Its value is driven primarily by the perceived promise of its pipeline, particularly the NLRP3 inhibitor program that analysts highlighted in late 2025 as having potential across obesity and cardiometabolic indications. For a stock of this type, price moves are often driven less by gradual fundamental progress than by discrete clinical-data events, financing decisions, and shifts in sentiment.
The clearest potential catalysts are positive clinical data readouts and pipeline progress. Late 2025 analyst commentary specifically cited the NLRP3 program as a potential driver of value creation across multiple large-market indications, including obesity and cardiometabolic disease. A successful financing that removes near-term capital concerns, renewed analyst coverage, or a broader recovery in biotech sentiment could also support a move higher. At such depressed levels, even a partial recovery in confidence can produce outsized percentage gains.
The risks are equally significant. As a clinical-stage company with negative earnings, Neumora depends on external capital, and future equity raises can dilute existing shareholders and pressure the share price. Binary clinical-trial outcomes mean that a single disappointing readout can sharply reset the valuation, as the stock's collapse from a 52-week high of $3.65 to a low near $0.32 appears to reflect. Competition in neuropsychiatric and metabolic drug development, regulatory hurdles, and broader risk-off conditions in small-cap biotech all represent additional obstacles.
The $1.00 level is a notable psychological round-number marker for a stock trading below it, and it stands well below the shares' prior trading range. The 52-week high near $3.65 and low near $0.32 frame an extraordinarily wide range, underscoring the stock's volatility. For a technical recovery, $1.00 would need to act first as resistance before any meaningful move toward prior levels.
Because no current analyst consensus exists, no standard research horizon applies to the $1.00 objective. Investors should instead monitor pipeline updates and clinical data, financing announcements, and any resumption of analyst coverage. Quarterly financial reports and updates on cash runway are also important given the company's clinical-stage, loss-making profile. No timing can be reliably forecast for a move of this magnitude.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a highly volatile name like NMRA, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual scanning. Explore the AI Daily Buy/Sell Signals to see how automated monitoring can support your market research.
The $1.00 objective for NMRA is a fallback recovery milestone rather than an analyst price target, and it implies a substantial, roughly 100% move from the current price near $0.50. The strongest support comes from the company's pipeline potential and any positive clinical or financing news, while the principal obstacles are a loss-making clinical-stage profile, dilution risk, and binary trial outcomes. The late-2025 analyst targets, which ranged from $3 to $14 with a mean near $7, are too stale to serve as a reliable guide after the stock's sharp decline. Investors should watch clinical data, financing, and any new analyst coverage closely, while recognizing that no outcome is assured.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with SLBT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then SLBT could also see price increases.
| Ticker / NAME | Correlation To NMRA | 1D Price Change % | ||
|---|---|---|---|---|
| NMRA | 100% | +34.99% | ||
| SLBT - NMRA | 44% Loosely correlated | +5.83% | ||
| CNTX - NMRA | 39% Loosely correlated | +6.82% | ||
| SNDX - NMRA | 35% Loosely correlated | -4.03% | ||
| CRVO - NMRA | 34% Loosely correlated | +2.50% | ||
| ADCT - NMRA | 33% Poorly correlated | +0.65% | ||
More | ||||